Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Work In Process (2021 - 2024)

Apellis Pharmaceuticals (APLS) has 4 years of Work In Process data on record, last reported at $106.2 million in Q1 2024.

  • For Q1 2024, Work In Process rose 119.02% year-over-year to $106.2 million; the TTM value through Mar 2024 reached $106.2 million, up 119.02%, while the annual FY2023 figure was $82.9 million, 53.28% up from the prior year.
  • Work In Process reached $106.2 million in Q1 2024 per APLS's latest filing, up from $82.9 million in the prior quarter.
  • Across five years, Work In Process topped out at $106.2 million in Q1 2024 and bottomed at $10.1 million in Q4 2021.
  • Average Work In Process over 4 years is $48.1 million, with a median of $48.4 million recorded in 2023.
  • Peak YoY movement for Work In Process: soared 437.89% in 2022, then soared 53.28% in 2023.
  • A 4-year view of Work In Process shows it stood at $10.1 million in 2021, then skyrocketed by 437.89% to $54.1 million in 2022, then skyrocketed by 53.28% to $82.9 million in 2023, then increased by 28.02% to $106.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Work In Process were $106.2 million in Q1 2024, $82.9 million in Q4 2023, and $52.1 million in Q3 2023.